LPM580098, a Novel Triple Reuptake Inhibitor of Serotonin, Noradrenaline, and Dopamine, Attenuates Neuropathic Pain
Background and Purpose: Sedation and somnolence remain serious adverse effects of the existing analgesics (e.g., pregabalin, duloxetine) for neuropathic pain. The available evidence indicates that serotonin (5-HT), noradrenaline (NE), and dopamine (DA) play important roles in modulating the descendi...
Saved in:
Main Authors: | Nannan Li (Author), Chunmei Li (Author), Rui Han (Author), Yu Wang (Author), Mina Yang (Author), Hongbo Wang (Author), Jingwei Tian (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2019-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Pharmacological Characterization of Toludesvenlafaxine as a Triple Reuptake Inhibitor
by: Haibo Zhu, et al.
Published: (2021) -
Lorcaserin Alters Serotonin and Noradrenaline Tissue Content and Their Interaction With Dopamine in the Rat Brain
by: Giuseppe Di Giovanni, et al.
Published: (2020) -
Epigenetic Mechanism of 5-HT/NE/DA Triple Reuptake Inhibitor on Adult Depression Susceptibility in Early Stress Mice
by: Ping Meng, et al.
Published: (2022) -
Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors
by: Chad Compagner, et al.
Published: (2021) -
LPM3770277, a Potent Novel CDK4/6 Degrader, Exerts Antitumor Effect Against Triple-Negative Breast Cancer
by: Jiahao Qiu, et al.
Published: (2022)